TY - JOUR
T1 - Cyclophosphamide, methotrexate, and 5-fluorouracil (CMF)-induced ocular toxicity
AU - Loprinzi, Charles L.
AU - Love, Richard R.
AU - Garrity, James A.
AU - Ames, Matthew M.
N1 - Funding Information:
The authors acknowledge Mary Kuffel for her help with 5-FU tear concentration measurements. This work was supported in patt by NM Grant CA 26235.
PY - 1990
Y1 - 1990
N2 - Ocular toxicity is a common, but poorly understood, sequela from CMF chemotherapy. We investigated this toxicity in patients receiving CMF therapy. Detailed interviews in 210 patients revealed that new, unpleasant ocular symptoms developed in 42% of patients receiving CMF, in 39% of subjects receiving other regimens containing 5-fluorouracil (5-FU), and only in 18% of subjects receiving a variety of chemotherapy regimens not containing 5-FU. CMF-associated ocular symptoms usually consisted of mild to marked tearing, ocular pruritis, and/or burning. These toxicities usually began 11-17 days after starting a cycle of CMF and lasted for 10-15 days. 5-FU was detected in the tears of 12 tested patients within several minutes after intravenous 5-FU (peak concentrations as high as 60 μg/ml). 5-FU tear concentrations did not correlate with the presence or absence of ocular toxicity. There is no established antidote for this toxicity although some patients have reported subjective benefit from cryotherapy, applied around the period of 5-FU injections, or cromolyn sodium eye drops.
AB - Ocular toxicity is a common, but poorly understood, sequela from CMF chemotherapy. We investigated this toxicity in patients receiving CMF therapy. Detailed interviews in 210 patients revealed that new, unpleasant ocular symptoms developed in 42% of patients receiving CMF, in 39% of subjects receiving other regimens containing 5-fluorouracil (5-FU), and only in 18% of subjects receiving a variety of chemotherapy regimens not containing 5-FU. CMF-associated ocular symptoms usually consisted of mild to marked tearing, ocular pruritis, and/or burning. These toxicities usually began 11-17 days after starting a cycle of CMF and lasted for 10-15 days. 5-FU was detected in the tears of 12 tested patients within several minutes after intravenous 5-FU (peak concentrations as high as 60 μg/ml). 5-FU tear concentrations did not correlate with the presence or absence of ocular toxicity. There is no established antidote for this toxicity although some patients have reported subjective benefit from cryotherapy, applied around the period of 5-FU injections, or cromolyn sodium eye drops.
UR - http://www.scopus.com/inward/record.url?scp=0025672845&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0025672845&partnerID=8YFLogxK
U2 - 10.3109/07357909009012068
DO - 10.3109/07357909009012068
M3 - Article
C2 - 2124943
AN - SCOPUS:0025672845
SN - 0735-7907
VL - 8
SP - 459
EP - 465
JO - Cancer Investigation
JF - Cancer Investigation
IS - 5
ER -